Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
Kevin Land, Interim Laboratory and Medical Director Adult HSC Lab at UPMC Hillman Cancer Center, shared a post on LinkedIn about a recent article he and his colleague co-authored, published in Transfusion, adding:
“The transfusion medicine physician has spent a career being cast as the cost-savings gatekeeper at many institutions.
Cellular therapy is handing the specialty a larger role in direct patient care.
Eric Gehrie, and I just published ‘Redefining the Role of the Transfusion Medicine Physician in the Era of Advanced Cellular Therapies’ in Transfusion – open access.
The growth in cellular collection and processing has pulled TM physicians (and the whole TM team) into new territory the specialty wasn’t necessarily trained for.
Grateful to AABB for the platform and to Eric for the collaboration.
Curious what others are seeing. Is your program stretching into cellular therapy oversight? If so, do you see anything differently than what we discussed?”
Title: Redefining the role of the transfusion medicine physician in the era of advanced cellular therapies
Authors: Eric A. Gehrie, Kevin J. Land
Other posts featuring Kevin Land on Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs